4/A: Sana Biotechnology Director Patrick Yang Corrects Stock Option Acquisition in Amended SEC Filing

Patrick Yang, a director at Sana Biotechnology, files an amended Form 4 to correct the number of stock options acquired on June 6, 2024.

Summary

• Patrick Yang, a director of Sana Biotechnology, Inc. [SANA], filed an amended Form 4 with the SEC on July 15, 2024, to correct a clerical error regarding the number of stock options acquired.
• The original transaction occurred on June 6, 2024, where Yang acquired stock options with an exercise price of $7.36.
• The corrected filing clarifies that Yang acquired 65,000 stock options.
• These options vest and become exercisable on the earlier of June 6, 2025, or immediately before the 2025 annual meeting of Sana stockholders, contingent upon continuous service to Sana through that date.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a clerical error. It doesn't contain any information that would significantly impact the company's valuation or investor sentiment, but transparency is generally viewed positively.

Future Outlook

The vesting of the stock options is contingent upon Patrick Yang's continuous service to Sana Biotechnology through the vesting date, indicating an expectation of continued involvement.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• Shareholders are informed about the corrected stock option acquisition by a company director, promoting transparency.

Key Dates